Startups
At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.
Overview
Employees
11-50
Founded date
2022
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 23, 2023 | Alaya.bio Acquires Key Assets From Ixaka France | Alaya.bio, a Villejuif, France- and Cambridge, MA-based in vivo gene delivery biotech company, acquired all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therap... |
Reviews 0
FAQ about Alaya.bio
When was Alaya.bio founded?
Alaya.bio was founded in 2022.
What has the press written about Alaya.bio?
Parsers VC has collected 2 articles mentioning Alaya.bio, among them “Alaya.bio Acquires Key Assets From Ixaka France” (Oct 23, 2023).
Is Alaya.bio still active?
Yes, Alaya.bio is active; its latest activity on Parsers VC dates from Sep 14, 2026.